Abstract
Bone marrow-derived dendritic cells have been used to treat established experimental tumors by unleashing a cellular immune response against tumor antigens. Such antigens are artificially loaded onto dendritic cells antigenpresenting molecules by different techniques including incubation with synthetic antigenic determinants, tumor lysates or nucleic acids encoding for those relevant antigens. Ex vivo gene transfer with viral and non-viral vectors is frequently used to obtain expression of the tumor antigens and thereby to formulate the therapeutic vaccines. Efficacy of the approaches is greatly enhanced if dendritic cells are transfected with a number of genes which encode immunostimulating factors. In some cases, such as with IL-12, IL-7 and CD40L genes, injection inside experimental malignancies of thus transfected dendritic cells induces complete tumor regression in several models. In this case tumor antigens are captured by dendritic cells by still unclear mechanisms and transported to lymphoid organs where productive antigen presentation to T-cells takes place. Many clinical trials testing dendritic cell-based vaccines against cancer are in progress and partial clinical efficacy has been already proved. Transfection of genes further strengthening the immunogenicity of such strategies will join the clinical club soon.
Keywords: Cytokine Gene Transfer, Dendritic Cells, immunostimulating, chemokine Receptor, Tumor Necrosis Factor, Interleukin, Secondary Lymphoid tissue Chemokine
Current Gene Therapy
Title: Cytokine Gene Transfer into Dendritic Cells for Cancer Treatment
Volume: 2 Issue: 1
Author(s): I. Tirapu, M. Rodriguez-Calvillo, C. Qian, M. Duarte, C. Smerdou, B. Palencia, G. Mazzolini, J. Prieto and I. Melero
Affiliation:
Keywords: Cytokine Gene Transfer, Dendritic Cells, immunostimulating, chemokine Receptor, Tumor Necrosis Factor, Interleukin, Secondary Lymphoid tissue Chemokine
Abstract: Bone marrow-derived dendritic cells have been used to treat established experimental tumors by unleashing a cellular immune response against tumor antigens. Such antigens are artificially loaded onto dendritic cells antigenpresenting molecules by different techniques including incubation with synthetic antigenic determinants, tumor lysates or nucleic acids encoding for those relevant antigens. Ex vivo gene transfer with viral and non-viral vectors is frequently used to obtain expression of the tumor antigens and thereby to formulate the therapeutic vaccines. Efficacy of the approaches is greatly enhanced if dendritic cells are transfected with a number of genes which encode immunostimulating factors. In some cases, such as with IL-12, IL-7 and CD40L genes, injection inside experimental malignancies of thus transfected dendritic cells induces complete tumor regression in several models. In this case tumor antigens are captured by dendritic cells by still unclear mechanisms and transported to lymphoid organs where productive antigen presentation to T-cells takes place. Many clinical trials testing dendritic cell-based vaccines against cancer are in progress and partial clinical efficacy has been already proved. Transfection of genes further strengthening the immunogenicity of such strategies will join the clinical club soon.
Export Options
About this article
Cite this article as:
Tirapu I., Rodriguez-Calvillo M., Qian C., Duarte M., Smerdou C., Palencia B., Mazzolini G., Prieto J. and Melero I., Cytokine Gene Transfer into Dendritic Cells for Cancer Treatment, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348192
DOI https://dx.doi.org/10.2174/1566523023348192 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPARγ Agonists in Combination Cancer Therapies
Current Cancer Drug Targets Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Anti-Cancer Agents in Medicinal Chemistry mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Cell Adhesion Molecules and Cadmium
Current Chemical Biology Treatment of Radiation Nephropathy with ACE Inhibitors and AII Type-1 and Type-2 Receptor Antagonists
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Dietary Antioxidants: Immunity and Host Defense
Current Topics in Medicinal Chemistry The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design